Illustration: Workgroup Seibel, VCH-Wiley

Sugar molecules

Sweet help for cancer detection

Scientists from the University of Würzburg have synthesized a complex sugar molecule which specifically binds to the tumor protein Galectin-1. This could help to recognize tumors at an early stage and to combat them in a targeted manner.

Galectins are a family of proteins that have become a promising source of cancer research in recent years. A representative thereof is galectin-1. It sits on the surface of all human cells; on tumor cells, however, it occurs in enormous quantities. This makes it an interesting target for diagnostics and therapy.

"Among other things, it is known that galectin-1 hides the tumor cells from the immune system," explains Professor Jürgen Seibel of the Institute of Organic Chemistry at the Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany. Recent studies have shown that when Galectin-1 is blocked, the immune system can recognize the tumor and attack it with T cells.

Sugar molecule with docking station

Photo
Like a spaceship, the complex sugar molecule (coloured) lands exactly on the tumor protein galectin-1, which here looks like a meteorite and is shown in black and white.
Source: Workgroup Seibel, VCH-Wiley

No wonder, therefore, that galectin-1 has become a major focus of research. Seibel and his colleague Dr. Clemens Grimm is interested in a very specific section of this protein, the so-called carbohydrate recognition domain. They have now designed a complex sugar molecule that fits perfectly into this domain, as the scientists report in journal "ChemBioChem".

"We have equipped the sugar molecule with a docking site, for example, to connect it with a fluorescent dye or an drug," says Seibel. In addition, the scientists have described the binding of their molecule to galectin-1 with high-resolution X-ray structure analyzes. "Our findings can serve the development of high-affinity ligands of the protein Galectin-1 and thus of new drugs," said Clemens Grimm.

Quick test for Galectin-1 in progress

Now the JMU scientists are working on a rapid test for the detection of galectin-1. It is designed to enable early detection of tumors such as neuroblastoma. For the future, Seibel's team would like to expand the sugar molecules into a kind of shuttle system that allows pharmaceutical agents to be transported directly to the tumors.


Source: University of Würzburg

16.08.2017

Related articles

Bioreactor

Cancer treatment models get real

Researchers at Rice University and University of Texas MD Anderson Cancer Center have developed a way to mimic the conditions under which cancer tumors grow in bones.

Multimodal imaging

Imaging probe yields double insight

An organic dye that can light up cancer cells for two powerful imaging techniques providing complementary diagnostic information has been developed and successfully tested in mice by A*STAR…

Biomarker validation

Plodding toward a pancreatic cancer screening test

Pancreatic cancer is one of the most deadly types of malignancies, with a 5-year survival rate after late diagnosis of only about 5%. The majority of patients—about 80%—receive their diagnosis…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

PET-CT

GE Healthcare Discovery IQ

GE Healthcare

PET-CT

GE Healthcare Discovery MI

GE Healthcare